WO2004004642A3 - TCELL TOLERANCE AND MODULATION OF AUTOIMMUNITY BY CD8α-CD4+ DENDRITIC CELLS - Google Patents

TCELL TOLERANCE AND MODULATION OF AUTOIMMUNITY BY CD8α-CD4+ DENDRITIC CELLS Download PDF

Info

Publication number
WO2004004642A3
WO2004004642A3 PCT/US2003/020848 US0320848W WO2004004642A3 WO 2004004642 A3 WO2004004642 A3 WO 2004004642A3 US 0320848 W US0320848 W US 0320848W WO 2004004642 A3 WO2004004642 A3 WO 2004004642A3
Authority
WO
WIPO (PCT)
Prior art keywords
dendritic cells
cd8α
tcell
autoimmunity
tolerance
Prior art date
Application number
PCT/US2003/020848
Other languages
French (fr)
Other versions
WO2004004642A2 (en
Inventor
Habib Zaghouani
Original Assignee
Univ Tennessee Res Corp
Habib Zaghouani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Corp, Habib Zaghouani filed Critical Univ Tennessee Res Corp
Priority to AU2003253780A priority Critical patent/AU2003253780A1/en
Publication of WO2004004642A2 publication Critical patent/WO2004004642A2/en
Publication of WO2004004642A3 publication Critical patent/WO2004004642A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invitation relates to compositions and methods for treatment of autoimmune disorders such as multiple sclerosis. More specifically, the present invention teaches the in vivo use of a subset of dendritic cells in conjunction with engineered immunoglobins containing a self-peptide which together have modulatory effects on tolerization of autoreactive T cells and sustain peripheral tolerance against self-antigens.
PCT/US2003/020848 2002-07-03 2003-07-02 TCELL TOLERANCE AND MODULATION OF AUTOIMMUNITY BY CD8α-CD4+ DENDRITIC CELLS WO2004004642A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003253780A AU2003253780A1 (en) 2002-07-03 2003-07-02 TCELL TOLERANCE AND MODULATION OF AUTOIMMUNITY BY CD8Alpha-CD4+ DENDRITIC CELLS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39393202P 2002-07-03 2002-07-03
US60/393,932 2002-07-03

Publications (2)

Publication Number Publication Date
WO2004004642A2 WO2004004642A2 (en) 2004-01-15
WO2004004642A3 true WO2004004642A3 (en) 2004-08-26

Family

ID=30115661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020848 WO2004004642A2 (en) 2002-07-03 2003-07-02 TCELL TOLERANCE AND MODULATION OF AUTOIMMUNITY BY CD8α-CD4+ DENDRITIC CELLS

Country Status (2)

Country Link
AU (1) AU2003253780A1 (en)
WO (1) WO2004004642A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US8603472B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8603471B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
EP2430153A4 (en) * 2009-05-13 2013-02-27 Gliknik Inc Methods of using immunoglobulin aggregates

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KUWANA M. ET AL: "Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets", HUMAN IMMUNOL., vol. 63, December 2002 (2002-12-01), pages 1156 - 1163, XP002978586 *
LEGGE K.L. ET AL: "Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis", J. EXP. MED., vol. 191, no. 12, 19 June 2000 (2000-06-19), pages 2039 - 2051, XP002970596 *
LEGGE K.L. ET AL: "Multi-modal antigen specific therapy for autoimmunity", INTERN. REV. IMMUNOL., vol. 20, October 2001 (2001-10-01), pages 593 - 611, XP002970594 *
LEGGE K.L. ET AL: "On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity", J. EXP. MED., vol. 196, no. 2, 8 March 2001 (2001-03-08), pages 217 - 227, XP002978571 *
MAHNKE K. ET AL: "Immature, but not inactive: the tolerogenic function of immature dendritic cells", IMMUNOL. CELL BIOL., vol. 80, 2002, pages 477 - 483, XP002978585 *
MENGES M. ET AL: "Repetitive Injections of Dendritic Cells Matured with Tumor Necrosis Factor Alpha Induce Antigen-specific Protection of Mice from Autoimmunity", J. EXP. MED., vol. 195, no. 1, 7 January 2002 (2002-01-07), pages 15 - 21, XP002978572 *
STEINMAN R.M. ET AL: "Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance", PNAS, vol. 99, no. 1, 8 January 2002 (2002-01-08), pages 351 - 358, XP002978573 *

Also Published As

Publication number Publication date
WO2004004642A2 (en) 2004-01-15
AU2003253780A1 (en) 2004-01-23
AU2003253780A8 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
WO2005070090A3 (en) Regulatory t cells suppress autoimmunity
TW200621736A (en) Mitotic kinesin inhibitors and methods of use thereof
WO2006050270A3 (en) Compositions and methods for treating hyperproliferative disorders
WO2005023866A3 (en) Peptides that inhibit complement activation
WO2004009558A3 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
WO2005034998A3 (en) Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2007047692A3 (en) Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna
WO2004080388A3 (en) Preparation of hyaluronic acid from eggshell membrane
WO2004091645A3 (en) Composition comprising rosmarinic acid, borneol and ginsenoside
WO2004003142A3 (en) Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2007146730A3 (en) Deacetylase inhibitor therapy
EP3760224A3 (en) Novel combinations for antigen based therapy
WO2007059031A3 (en) Methods and compositions for raising levels and release of gamma aminobutyric acid
WO2005042727A3 (en) Methods of organ regeneration
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2004004642A3 (en) TCELL TOLERANCE AND MODULATION OF AUTOIMMUNITY BY CD8α-CD4+ DENDRITIC CELLS
WO2007015175A3 (en) Use of pp-1 inhibitors to prevent missplicing events
WO2004032864A3 (en) X-nitro compounds, pharmaceutical compositions thereof and uses therof
WO2005079271A3 (en) Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
WO2004064766A3 (en) Method of treatment of conditions by administration of streptolysin o
WO2005014008A3 (en) Treatment of disorders associated with natural killer t cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP